HK Stock MarketDetailed Quotes

CF PHARMTECH (02652)

Watchlist
  • 37.760
  • +0.620+1.67%
Market Closed Dec 5 15:59 CST
15.56BMarket Cap517.26P/E (TTM)

About CF PHARMTECH Company

In 2007, the company was founded in Jiangsu Province. The company focuses on the respiratory system segment. It is an international market-oriented professional pharmaceutical enterprise integrating R&D, production and sales.

Company Profile

Symbol02652
Company NameCF PHARMTECH
ISINCNE1000074R9
Listing DateOct 8, 2025
Issue Price14.75
Shares Offered41.20M share(s)
FoundedJan 24, 2013
Registered AddressChina
Chairmanwenqing liang
Secretaryzhuotingzhuyuyu zhu
Audit InstitutionErnst & Young
Company CategoryOther
Registered OfficeNo. 16, Hucundang Road, Xiangcheng Economic Development Zone, Suzhou, Jiangsu, China
Head Office and Principal Place of Business31st Floor, Tower 2, Times Square, 1 Matheson Street, Causeway Bay, Hong Kong
Fiscal Year Ends12-31
Employees574
MarketHong Kong motherboard
Phone(86)51266188089
Emailir@cfpharmtech.com
Websitehttp://www.cfpharmtech.com
Business Changfeng Pharmaceutical Co., Ltd. is a Chinese company focusing on the R&D, production and commercialization of inhalation technology and inhaled drugs. The company's product portfolio mainly targets respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and allergic rhinitis. The company's main products include CF017, an inhaled budesonide suspension to treat bronchial asthma, and CF018, an azastine fluticasone nasal spray for the treatment of allergic rhinitis.

Company Executives

  • Name
  • Position
  • Salary
  • wenqing liang
  • Chairman, CEOs, Executive Director, Member of the Remuneration and Assessment Committee, Co-founder, Authorized Representative
  • 2.64M
  • li li
  • Executive Director, Chief Scientist, Director of Jiangsu Changfeng, Co-founder
  • 2.52M
  • qi li
  • Executive Director, Chief Operating Officer, Director of the Pharmaceutical Research Institute
  • 1.30M
  • yuyu zhu
  • Executive Director, Deputy General Manager, Joint Company Secretary, Board Secretary, Nomination Committee Members
  • 924.00K
  • penghui chen
  • Non-executive Directors
  • --
  • lei cai
  • Non-executive Directors
  • --
  • hua yi
  • Non-executive Directors
  • --
  • jian jin
  • Independent Non-Executive Director, Audit Committee Members, Nomination Committee Members
  • 60.00K
  • lijuan wang
  • Independent Non-Executive Director, Chairman of the Audit Committee
  • 60.00K
  • shirong wei
  • Independent Non-Executive Director, Chairman of the Nomination Committee, Member of the Remuneration and Assessment Committee
  • 60.00K
  • yunkai ye
  • Independent Non-Executive Director, Chairman of the Remuneration and Assessment Committee, Audit Committee Members
  • 50.00K
  • jingjing zhang
  • Suzhou Changfeng Health Supervisor, Chairman of the Supervisory Board
  • --
  • xiangfeng cheng
  • Supervisor of Suzhou Changfeng Pharmaceutical, Auditors
  • --
  • jingjing kuai
  • Supervisors of Jiangsu Changfeng and Suzhou Changfeng Equipment, Auditors
  • --
  • wei wei
  • Head of Finance
  • --
  • zhuoting zhu
  • Joint Company Secretary, Authorized Representative
  • --
Market Insights
HK Tech and Internet Stocks
No. Symbol 5D % Chg
Sample Name
Sample Code
 +6.85%
Sample Name
Sample Code
 +4.29%
Sample Name
Sample Code
 +3.64%
4
TME-SW
01698
+2.66%
5
BABA-W
09988
+2.31%
View More
Nancy Pelosi Portfolio
No. Symbol % Chg
Sample Name
Sample Code
 +3.66%
Sample Name
Sample Code
 +3.38%
Sample Name
Sample Code
 +2.58%
4
Clean Energy Fuels
CLNE
+2.17%
5
NVIDIA
NVDA
+2.12%
Will the 'tariff stick' strike again? Will the market remain 'reactive'?
China and the United States have successively adjusted multiple tariff and non-tariff measures, beginning to implement the consensus outcome Show More
[Opportunity Express] The US-China rivalry escalates! The rare earth industry becomes a "game-changer." How should investors respond?
"Leaving the Group - Raising Taxes - Tweeting: The 'Money Making Strategy' of the Most Wild Gemini in Contemporary Times"

- No more -